S&P Futures
3,812.25 -15.00 (-0.39%) Dow Futures
30,948.00 -113.00 (-0.36%) Nasdaq Futures
11,560.25 -51.00 (-0.44%) Russell 2000 Futures
1,719.30 -9.20 (-0.53%) Crude Oil
110.30 +1.87 (+1.72%) Gold
1,807.40 +5.90 (+0.33%)
Edgewise Therapeutics, Inc. (EWTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 7.96 |
| Open | 7.97 |
| Bid | 7.70 x 1100 |
| Ask | 9.00 x 1100 |
| Day's Range | 7.80 - 8.17 |
| 52 Week Range | 5.41 - 24.30 |
| Volume | |
| Avg. Volume | 241,806 |
| Market Cap | 398.31M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.43 |
| Earnings Date | Nov 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.00 |
- Benzinga
RBC Capital Says This Dystrophy Stock 'Is Worth A Look'
RBC Capital says Edgewise Therapeutics Inc's (NASDAQ: EWTX) interim results from the ARCH study of EDG-5506 in Becker Muscular Dystrophy (BMD) improve reward/risk into October functional readout at 15 mg, which can help further de-risk the asset into the phase 2 BMD and Duchenne muscular dystrophy (DMD) studies. The analysts believe stable patient NSAAs in October readout can potentially drive shares up 100% and further improve the setup into 2Q23 placebo-controlled randomized DMD readout and 2H
- Benzinga
Edgewise's Dystrophy Candidate Lowers Muscle Damage Biomarkers
Edgewise Therapeutics Inc (NASDAQ: EWTX) announced 2-month interim results from the ARCH study of EDG-5506 in adults with Becker Muscular Dystrophy (BMD). EDG-5506 was well-tolerated with no discontinuations or dose reductions. The most common adverse events observed at the 10 mg dose were dizziness (17%) and somnolence (17%). These were generally transient and typically observed in the first few days of dosing. All patients have subsequently been dose-escalated to 15 mg daily as per protocol. R
- Business Wire
Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
BOULDER, Colo., June 20, 2022--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month interim results from the ongoing ARCH study, an open label, single-center study assessing the safety, tolerability, impact on muscle damage biomarkers, and pharmacokinetics (PK) of EDG-5506 in adults with BMD. EDG-5506 is an orally admi
